Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

d other current assets 1,208,000 1,188,000

Total current assets 19,843,000 19,898,000

PROPERTY:

Leasehold improvements 669,000 646,000

Laboratory equipment 4,140,000 3,533,000

Furniture, fixtures and computer equipment 919,000 873,000

5,728,000 5,052,000

Less accumulated depreciation and

amortization (3,670,000) (3,212,000)

Property, net 2,058,000 1,840,000

Other assets 1,156,000 1,259,000

TOTAL ASSETS $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

AS OF APRIL 30, 2008 AND 2007 (continued)

2008 2007

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $2,060,000 $1,683,000

Accrued clinical trial site fees 237,000 228,000

Accrued legal and accounting fees 450,000 392,000

Accrued royalties and license fees 222,000 337,000

Accrued payroll and related costs 1,084,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 22,000 17,000

Deferred revenue 2,196,000 1,060,000

Customer deposits 838,000 585,000

Other current liabilities 331,000 300,000

Total current liabilities 7,440,000 5,855,000 '/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... drought and insect pressures , Syngenta ... grand opening celebration today at the company’s RTP Innovation ... Crop Lab allows company researchers to simulate any agricultural ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... A new Hospital Energy Performance Service ... energy efficiency by 25% or more ... low-cost modifications. The service is available from ... Massachusetts-based environmental and engineering consulting firm."Healthcare facilities are heavy energy ...
... particle (VLP) vaccine progresses with study designed to select ... Novavax, Inc. (Nasdaq: NVAX ) announced ... trial of its virus-like particle (VLP) seasonal influenza vaccine. ... II randomized, placebo controlled clinical trial has been designed ...
... May 5 Novagali Pharma, a French,pharmaceutical ... New Drug Application (IND) to conduct a ... the treatment of glaucoma has been,granted by ... Catioprost(R) is a,topical ocular proprietary BAK-free formulation ...
Cached Biology Technology:New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... a fast food restaurant had a higher body mass ... fast food, according to researchers at The University of ... particularly strong among those with a lower income. ... American Journal of Public Health indicates higher BMI ... and among lower-income African-Americans, the density, or number, of ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... time, scientists have identified an ant species that produces ... , Stanford University biologist Deborah M. Gordon and her ... of the journal Nature. The discovery was made during ... Megan E. Frederickson in the Amazon jungle of western ...
... been the gold standard for treating newborns suffering from ... are superior to sedatives for treating infants born to ... Opiates appear to better "ameliorate the withdrawal, facilitate feeding ... two new systematic reviews done by David Osborn, a ...
... ?"blue gold" on the international deep sea floor ... new report from the Japan-based United Nations University ... as important to humankind for their potential medical ... more accessible and vulnerable than ever because of ...
Cached Biology News:Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 2Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 3Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 4Opiates Better Than Sedatives For Treating Newborns In Withdrawal 2A Father’s Day Gift: Free DNA Paternity Testing 2A Father’s Day Gift: Free DNA Paternity Testing 3A Father’s Day Gift: Free DNA Paternity Testing 4A Father’s Day Gift: Free DNA Paternity Testing 5
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Biology Products: